Estrogen receptors α and β: Prevalence of estrogen receptor β mRNA in human vascular smooth muscle and transcriptional effects

Circulation

Volumn 101, Issue 15, 2000, Pages 1792-1798

  Hodges, Yvonne K ^a   Tung, Lin ^a   Yan, Xiang Dong ^a   Graham, J Dinny ^a   Horwitz, Kathryn B ^a   Horwitz, Lawrence D ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

Coronary disease; Human; Muscle, smooth; Receptors, estrogen

Indexed keywords

ESTRADIOL; ESTROGEN RECEPTOR; MESSENGER RNA; RECEPTOR SUBTYPE; TAMOXIFEN;

ADOLESCENT; ADULT; AGED; ARTICLE; CORONARY ARTERY DISEASE; GENETIC TRANSCRIPTION; HELA CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; LIGAND BINDING; PRIORITY JOURNAL; PROMOTER REGION; RECEPTOR DENSITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSACTIVATION; VASCULAR SMOOTH MUSCLE;

EID: 0034681917     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.101.15.1792     Document Type: Article

References (29)

1. Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med. 1991;20:47-63.
2. Skafar DF, Xu R, Ram J, Sowers JR. Female sex hormones and cardiovascular disease in women. J Clin Endocrinol Metab. 1997;82: 3913-3918.
3. Chen S, Li H, Durand J, Oparil S, Chen Y-F. Estrogen reduces myointimal proliferation after balloon injury of rat carotid artery. Circulation. 1996;93:577-84.
4. Kolodgie FD, Jacob A, Wilson PS, Carlson GC, Frab A, Verma A, Virmani R. Estradiol attenuates directed migration of vascular smooth muscle cells in vitro. Am J Pathol. 1996;148:969-976.
5. Horwitz KB, Horwitz LD. Canine vascular tissues are targets for androgens, estrogens, progestins, and glucocorticoids. J Clin Invest. 1982; 69:750-758.
6. Kumar V, Green S, Sftack G, Berry M, Jinn J, Chambon P. Functional domains of the human estrogen receptor. Cell. 1987;51:941-945.
7. Kuiper GGJM, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson JA. Cloning of a novel estrogen receptor expressed in rat prostate and ovary. Proc Nat Acad Sci U S A. 1996;93:5925-5930.
8. Mosselman S, Polman J, Dijkema R. ERβ: identification and characterization of a novel human estrogen receptor. FEBS Lett. 1996;392:49-53.
9. Pace P, Taylor J, Suntharalingam S, Coombes RC, Ali S. Human estrogen receptor beta binds DNA in a manner similar to and dimerizes with estrogen receptor alpha. J Biol Chem. 1997;272:25832-25838.
10. McInerney EM, Katzenellenbogen BS. Different regions in activation function-1 of the human estrogen receptor required for antiestrogen-and estradiol-dependent transcription activation. J Biol Chem. 1996;27: 24172-24178.
11. Kuiper GG, Carlsson B, Grandien K, Enmark E, Haggblad J, Nilsson S, Gustafsson JA. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology 1997;138:863-870.
12. Iafrati MD, Karas RH, Aronovitz M, Kim S, Sullivan TR Jr, Lubahn DB, O'Donnell TAF Jr, Horach KS, Mendelsohn ME. Estrogen inhibits the vascular injury response in estrogen receptor alpha-deficient mice. Nat Med. 1997;3:545-548.
13. Register TC, Adams MR. Coronary artery and cultured aortic smooth muscle cells express mRNA for both the classical estrogen receptor and the newly described estrogen receptor beta. J Steroid Biochem Mol Biol. 1998;64:187-191.
14. Hodges YK, Richer JK, Horwitz KB, Horwitz LD. Variant estrogen and progesterone messages in human vascular smooth muscle. Circulation. 1999;99:2688-2693.
15. Klein-Hitpass L, Schorpp M, Wagner U, Ryffel GU. An estrogen responsive element derived from the 5′ flanking region of the xenopus vitellogenin A-2 gene functions in transfected human cells. Cell. 1986; 46:1053-1061.
16. Sartorius CA, Melville MY, Hovland AR, Tung L, Takimoto GS, Horwitz KB. A third transactivation function (AF3) of human progesterone receptors located in the unique N-terminal segment of the B-isoform. Mol Endocrinol. 1994;8:1347-1360.
17. Hovland AR, Powell RL, Takimoto GS, Tung L, Horwitz KB. An N-terminal inhibitory function, IF, suppresses transcription by the A-isoform but not the B-isoform of human progesterone receptors. J Biol Chem. 1998;273:5455-5460.
18. Paech K, Webb P, Kuiper GGJM, Nilsson S, Gustafsson J-A, Kushner PJ, Scanlan T. Differential ligand activation of estrogen receptors ERα and ERβ at AP1 sites. Science. 1997;277:1508-1510.
19. Jackson TA, Richer JK, Bain DL, Takimoto GS, Tung L, Horwitz KB. The partial agonist activity of antagonist-occupied steroid receptors is controlled by a novel hinge domain-binding coactivator L7/SPA and the corepressors N-CoR or SMRT. Mol Endocrinol. 1997;11:693-705.
20. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E. Randomized trial of estrogen plus progestin for secondary prevention of coronary artery disease in postmenopausal women: heart and estrogen/progestin replacement study (HERS) research group. JAMA. 1998;280:605-613.
21. Williams JK, Honore EK, Washburn SA, Clarkson TB. Effects of hormone replacement therapy on reactivity of atherosclerotic coronary arteries in cynomolgus monkeys. J Am Coll Cardiol. 1994;24:1757-1761.
22. Miyagawa K, Roch J, Stanczyk F, Hersmeyer K. Medroxyprogesterone interfered with ovarian steroid protection against coronary vasospasm. Nat Med. 1997;3:324-327.
23. Selzman CH, Gaynor JS, Turner AS, Johnson SM, Horwitz LD, Whitehill TA, Harken AH. Ovarian ablation alone promotes aortic intimal hyperplasia and accumulation of fibroblast growth factor. Circulation. 1998; 98:2049-2054.
24. Chaidarun SS, Swearingen B, Alexander JM. Differential expression of estrogen receptor-β (ERβ) in human pituitary tumors: functional interactions with ERα and a tumor-specific splice variant. J Clin Endocrinol Metab. 1998;83:3308-3315.
25. Inoue S, Hoshino S, Miyoshi H, Akishita M, Hosoi T, Orimo H, Ouchi Y. Identification of a novel isoform of estrogen receptor, a potential inhibitor of estrogen action, in vascular smooth muscle cells. Biochem Biophys Res Commun. 1996;219:766-772.
26. Berry M, Metzger D, Chambon P. Role of the two activating domains of the oestrogen receptor in the cell-type and promoter-context dependent agonistic activity of the anti-oestrogen 4-hydroxytamoxifen. EMBO J. 1990;9:92811-92818.
27. Brzozowski AM, Pike ACW, Dauter Z, Hubbard RE, Bonn T, Engstrom O, Ohman L, Greene GL, Gustaffson JA, Carlquist M. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature. 1997;389: 753-758.
28. Nichols M, Rientjes JM, Stewart AF. Different positioning of the ligand-binding domain helix 12 and the F domain of the estrogen receptor accounts for functional differences between agonists and antagonists. EMBO J. 1998;17:765-773.
29. Watanabe T, Inoue S, Ogawa S, Ishii Y, Hiroi H, Ikeda K, Orimo A, Muramatsu M. Agonistic effect of tamoxifen is dependent on cell type, ERE-promoter context, and estrogen receptor subtype: functional difference between estrogen receptors alpha and beta. Biochem Biophys Res Commun. 1997;236:140-145.